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Abstract: Malabsorption, weight loss and vitamin/mineral-deficiencies characterize 
classical celiac disease (CD). This study aimed to assess the nutritional and 
vitamin/mineral status of current “early diagnosed” untreated adult CD-patients in the 
Netherlands. Newly diagnosed adult CD-patients were included (n = 80, 42.8 ± 15.1 years) 
and a comparable sample of 24 healthy Dutch subjects was added to compare vitamin 
concentrations. Nutritional status and serum concentrations of folic acid, vitamin A, B6, 
B12, and (25-hydroxy) D, zinc, haemoglobin (Hb) and ferritin were determined (before 
prescribing gluten free diet). Almost all CD-patients (87%) had at least one value below 
the lower limit of reference. Specifically, for vitamin A, 7.5% of patients showed deficient 
levels, for vitamin B6 14.5%, folic acid 20%, and vitamin B12 19%. Likewise, zinc 
deficiency was observed in 67% of the CD-patients, 46% had decreased iron storage, and 
32% had anaemia. Overall, 17% were malnourished (>10% undesired weight loss), 22% of 
the women were underweight (Body Mass Index (BMI) < 18.5), and 29% of the patients 
were overweight (BMI > 25). Vitamin deficiencies were barely seen in healthy controls, 
with the exception of vitamin B12. Vitamin/mineral deficiencies were counter-intuitively 
not associated with a (higher) grade of histological intestinal damage or (impaired) 
nutritional status. In conclusion, vitamin/mineral deficiencies are still common in newly 
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“early diagnosed” CD-patients, even though the prevalence of obesity at initial diagnosis is 
rising. Extensive nutritional assessments seem warranted to guide nutritional advices and 
follow-up in CD treatment. 
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1. Introduction 
Celiac disease (CD) is the most common food intolerance in the Western population, and currently 
represents a major health care issue. The prevalence of CD has been estimate to be 0.5%–1% in 
different parts of the world [1]. CD is an inflammatory, immune-mediated chronic disease of the 
mucosa of the proximal small intestine due to irreversible gluten intolerance in genetically susceptible 
individuals. Gluten refers to a set of amino acid sequences found in the prolamine fraction of wheat, 
barley and rye. The characteristic histopathological finding is a varying degree of villous atrophy and 
crypt hyperplasia, primarily in the duodenum and jejunum, with inflammatory changes leading to 
malabsorption. The first-line, and up-till-now only, treatment is a lifelong strict adherence to a gluten 
free diet (GFD). All other treatment modalities suppress the intestinal inflammatory response and do 
not treat the intolerance [2,3]. 
CD is a multi-system disorder which leads to striking differences in its clinical presentation. When 
present, gastrointestinal symptoms, including clinically evident malabsorption, may facilitate the 
diagnosis of CD. Over the last few decades, there appeared to be a changing clinical presentation of CD 
from the classical malabsorptive picture (diarrhoea, malabsorption and weight loss) towards one of a  
non-classical presentation with milder, non-specific symptoms such as tiredness, hematologic 
abnormalities, constipation and/or abdominal distension [4–6]. Nowadays, many patients present with no 
or only minor extra-intestinal symptoms. Indeed, microcytic or macrocytic anaemia, or folate deficiency 
may occasionally be the only clinical symptom to suggest CD. This leads to a great extent of 
underdiagnoses in several countries [7]. Currently, 20%–40% of newly diagnosed CD-patients are   
even classified as overweight (Body Mass Index (BMI) > 25 kg/m
2) instead of the anticipated   
underweight [8–12], although the prevalence of obesity seems lower than in the general population [13]. 
This makes the diagnosis of CD challenging. Greater clinical awareness—especially improved 
serological testing since the late 1990s, including that for anti-tissue transglutaminase (tTG)   
antibodies [14,15]—and the appearance of specialized centres has led to earlier recognition   
of CD-patients. 
In the classically presenting CD-patients, malabsorption is frequently encountered [16], and 
micronutrient deficiencies may arise. Indeed, several studies demonstrate these deficiencies with 
varying results [17–21]. 
Our group recently demonstrated the specific functional insufficiency of the proximal small bowel 
in CD-patients by means of the citrulline generation test, in which the citrulline peak after glutamine 
administration and its conversion into citrulline in the enterocyte was delayed due to a decreased 
functional intestinal mass as a consequence of inflammatory changes [22]. Nutrients 2013, 5  3977 
 
Deficiencies of water-soluble vitamins, like B-vitamins, would be expected since they are absorbed 
in the proximal small bowel, which is the most prominent site affected in CD-patients. However, 
available data, in particular regarding vitamin B2 and B6 deficiencies, do not support this in untreated 
CD-patients [17,23]. Table 1 shows an overview of older and more recent literature on vitamin and 
mineral deficiencies in adult CD-patients. 
Table 1. Literature overview on vitamin and mineral status in newly diagnosed adult celiac 
disease (CD)-patients. 
Author, year  Patient Group  Outcome  
Till 2005 
Hallert,1981 [24]  CD (Folate) 
Decreased serum folate concentration abnormality in 
adult CD. Predictive value of low folate for advice 
jejunal biopsy. 
Stene-Larsen, 1988 [25] 
CD (n = 3) 
 
Vitamin B12 malabsorption by CD is emphasized as a 
pathogenic mechanism of megaloblastic anaemia. 
Crofton, 1990 [20] 
Untreated CD (n = 8)  
and healthy controls (n = 5)  
(Zinc) 
Impaired turnover and loss of endogenous zinc in mild 
untreated CD. Zinc levels normal. 
Kemppainen, 1995 [26] 
Untreated CD (n = 40),  
CD in remission (n = 52) 
(Nutritional status) 
Nutritional status quite good in both groups.  
15%–38% deficiencies (HB, ferritin, iron or B12) in 
untreated CD compared to 0%–20% in remission CD.
Kemppainen, 1998 [27] 
Untreated CD (n = 40)  
(Nutritional status)  
Anthropometric and biochemical nutritional status 
acceptable. Low ferritin and folate (enterocyte) levels, 
but normalised after 1 year GFD. 
Alwitry, 2000 [23] 
Celiac disease  
(Vitamin A) 
Case report in vitamin A deficiency and eye deviation
Dahele, 2001 [18] 
 
Untreated CD (n = 39)  
(Vitamin B12) 
41% B12 deficient (<220 ng/L), 41% anaemic, and 
31% folate deficient f the B12 deficient CD-patients. 
Dickey, 2002 [28] 
CD (n = 159)  
(Vitamin B12) 
Low serum B12 is common in CD (12%) and is not due 
to autoimmune gastritis. 10% of B12 deficient group 
had atrophic gastritis. Advice to know B12 level before 
folate supplementation. 
Hozyasz, 2003 [29] 
 
Untreated CD Polish (n = 18), 
remission on GFD (n = 12)  
(Vitamin E) 
All untreated CD-patients had reduced vitamin E 
levels. Vitamin A comparable to treated CD. 
2005–2013 
Harper, 2007 [30] 
Untreated (3 mo after 
diagnosis) CD (n = 405)  
(Anaemia) 
Iron deficiency in 31% of male and 19% of females, 
folate in 12%, B12 5% and anaemia in 20% of  
CD-patients. Anaemia can not only be explained by 
nutritional deficiencies. 
Dickey, 2008 [17] 
Untreated CD (n = 35), 
persistent villous atrophy  
(n = 34, recovered (n = 41)  
(B-vitamins) 
No compromised B2 and B6 in 3 groups. 
Homocysteine concentrations are inversely associated 
with serum and red cell folate and with B12.  
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Table 1. Cont. 
Henri-Bhargava, 2008 [19] CD (Vitamin E, copper) 
Neurological impairment due to vitamin E and 
copper deficiencies in CD. 
Bergamaschi, 2008 [21] 
Untreated CD (n = 150), after 
1 year GFD (n = 53)  
(Anaemia) 
34% anaemia at diagnosis. Iron, vitamin 
deficiencies and anaemia of chronic disease are 
common in CD. GFD treatment improves anaemia.
Lerner, 2012 [31] 
CD (Spanish) (n = 22) and 
CD children (n = 120) 
(Spanish, Israeli),  
(Vitamin D) 
Vitamin D levels correlate negatively with age. 
55% of Adult CD-patients had vitamin D 
deficiency (25-hydroxy < 20 ng/mL) and  
should be supplemented. 
It has been suggested that the current “early diagnosis” of CD might be associated with less vitamin 
and mineral deficiencies at the moment of diagnosis than the classical CD. Mineral and trace-element 
status of untreated CD-patients has not been widely studied. There is even a lack of recent reports in 
the literature (see Table 1) indicating which deficiencies should be checked in newly diagnosed celiacs 
in Western Europe. Therefore, we aimed to measure essential serum nutritional variables in order to 
assess the prevalence of vitamin and mineral deficiencies in untreated adult CD-patients from a tertiary 
referral Celiac Disease Centre, consuming a (gluten containing) standard Dutch (Western) diet before 
diagnosis. Secondly, we studied the nutritional status and differences in prevalence of vitamin and 
mineral deficiencies between patients with different grades of intestinal histological damage, 
nutritional status, and sex. 
2. Materials and Methods 
2.1. Patients 
Eighty consecutively diagnosed adult patients (aged 18–75 years) with newly diagnosed CD were 
recruited from the Outpatient Clinic of the VU University Medical Centre, Amsterdam, the 
Netherlands, during the period 2005–2012. All patients consumed a normal (gluten-containing)   
Dutch-Western diet until inclusion. The mean daily gluten intake in the Netherlands is around   
13 g [32]. Duodenal biopsy specimens were harvested to determine the grade of histological damage 
due to gluten sensitive enteropathy as classified by Marsh [33] and modified by Rostami [34,35]. 
Gastric (corpus) biopsies were routinely harvested to determine whether atrophic gastritis was present. 
CD associated antibodies, i.e., anti-endomysial antibodies (EMA) and anti-tTG antibodies, were 
determined [36,37]. In addition, HLA-genotyping was performed, to analyse the presence of DQ2 and 
DQ8 (heterozygote or homozygote) as a prerequisite for a definitive diagnosis [38]. The diagnosis of 
CD was based on these histopathological, serological and genetic criteria. 
Histopathological classification according to Marsh was used: intraepithelial lymphocytosis, crypt 
hyperplasia and villous atrophy Marsh IIIA, B and C (respectively, partial, subtotal and total villous 
atrophy) with or without elevated antibodies. Also, a group was added with low grade histopathological 
abnormalities Marsh I or Marsh II (lymphocytic enteritis with crypt hyperplasia) with gluten-dependent 
disorders, in case of elevated antibodies and the HLA-DQ2 or HLA-DQ8 genotype. Nutrients 2013, 5  3979 
 
Blood samples were collected as part of routine clinical care. Patients were excluded if they had an 
established or suspected gastrointestinal abnormality other than CD, such as inflammatory bowel 
disease (IBD). A representative sample of 24 healthy Dutch subjects (comparable for sex, age and 
BMI) was added to compare concentrations of vitamin A, B6, folic acid and B12 (see control subjects 
characteristics [39]). Both groups were studied in the same period, were living in a similar 
environment, and measurements were performed at the same clinical chemistry laboratory. 
The study protocol was approved by the Medical Ethics Committee (2005, project code 05.153) of 
the VU University Medical Centre Amsterdam, The Netherlands. 
2.2. Nutritional Status 
Patient characteristics and demographic data (including age (year), body height (m), body weight (kg) 
and self-reported involuntary weight loss in the past 1 and 6 months) were collected, BMI was 
calculated and biochemical analyses were performed following diagnosis and before any dietary 
advice to initiate a GFD. Patients were subsequently classified as “malnourished” when they 
unintentionally lost more than 10% of their bodyweight in the past 6 months or more than 5% in the 
past month prior to diagnosis or as having “risk of malnutrition” when 5%–10% of the bodyweight 
was unintentionally lost in the 6 months before diagnosis. Moreover, patients were classified into  
3 groups on the basis of baseline BMI; less than 18.5 kg/m
2 (underweight), 18.5–25.0 kg/m
2 (normal 
weight) and more than 25 kg/m
2 (overweight, or even “obese” in case of BMI above 30 kg/m
2) 
(according to the definition of the World Health Organisation (2000)). 
2.3. Biochemical Analysis 
Fasting venous blood samples were drawn and subsequently analysed at the endocrine and clinical 
chemistry laboratories of the VU University Medical Centre, Amsterdam. Samples for serum folic acid 
and serum vitamin B12 were analysed by competitive immunoassay (Luminescence, Abbott, IL, USA). 
Serum vitamin B6 and vitamin A status were determined by high-performance liquid chromatography 
(HPLC). Vitamin (25-hydroxy) D was assessed with a competitive binding protein assay (Diasorin, 
Stillwater, MN, USA). Zinc status was assessed using Flame Atomic Absorption Spectroscopy 
(FAAS), serum haemoglobin by colorimetric methods (Cell Dyn Sapphire, Abbott, IL, USA) and 
ferritin values by electro-chemiluminescence immunoassay “ECLIA” (Roche, Mannheim, Germany) 
or “ACS CENTAUR” (Bayer, Mijdrecht, The Netherlands). 
Vitamin B6 and folic acid (both proximally absorbed) and vitamin B12 (distally absorbed) were 
considered to represent the water-soluble vitamin status. Vitamin A and vitamin (25-hydroxy) D were 
considered to represent the fat-soluble vitamin status, although sun exposure, even in The Netherlands, 
may have a strong influence on serum levels of vitamin D. Haemoglobin and ferritin levels below the 
reference ranges listed were used to establish a respective diagnosis of anaemia, iron-deficiency or 
iron-deficiency anaemia when both haemoglobin and ferritin were below reference ranges. Patients 
with a serum value below the lower limit of the reference value were considered “deficient”. Reference 
values for the different parameters are displayed in Table 3. 
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2.4. Statistical Analysis 
Data were tested for normal distribution and presented as means ± SD. The percentage of patients 
with values below the reference value and absolute number of deficient patients were additionally 
calculated for all assessed serum vitamin and mineral concentrations. 
Data were analysed for the total group, and in stratified subgroups by sex, histological damage 
(Marsh classification) and BMI. To determine differences with regard to gender, a Student’s t-test was 
applied in case of continuous data and Pearson’s Chi-Square tests (χ²) in the case of comparing 
proportions (% of deficient patients). Analysis of variance (ANOVA), with a Bonferroni correction 
when a statistical significant difference was achieved, was used to compare more than two groups. A 
Mann-Whitney U test (Wilcoxon) or in case of more than 2 variables, a Kruskal-Wallis test was 
applied for variables not found in a normal distribution. The level of statistical significance was 
determined a priori at p < 0.05. Statistical analyses were performed using SPSS (Statistical Package for 
Social Sciences Inc., Chicago, IL, USA—Windows version 20.0). 
3. Results 
3.1. Patient Characteristics and Nutritional Status 
Patient characteristics are shown in Table 2; two-thirds of the population was female. Male patients 
were significantly older than female patients (p = 0.006). Approximately 46% (37/80) of the patients had 
partial villous atrophy (Marsh IIIA) and 42.5% showed subtotal (20/80) or total villous atrophy (14/80) 
(Marsh IIIB or IIIC, respectively). Histologically and serologically atrophic (corpus) gastritis was ruled 
out by a pathologist experienced in intestinal histology. Some of the CD patients reported to have used 
vitamin and mineral supplements before diagnosis of CD was made: 18 (22.5%) a multivitamin, folic 
acid or vitamin B-complex, 7 (8.8%) iron supplements and 14 (17.5%) a calcium supplement. The 
anthropometric data of 24 healthy controls were comparable to those of the patients included. 
Patients had, on average, lost 2.4% (±6.3%) of their bodyweight during the 6 months prior to 
diagnosis. Approximately 17% was classified as malnourished (>10% weight loss) and 5% as being at 
risk of malnutrition (5%–10% previous weight loss). Six out of 80 patients (7.5%), and only females, 
were classified as underweight, whereas 29% (23/80) of patients were classified as overweight   
(female:male ratio =1:1). Of the overweight patients, 26% were even obese (6/80 of the total group, 
with female:male ratio = 1:1). 
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Table 2. Patient characteristics of untreated adult CD-patients by gender and compared to 
healthy controls. 
CD Patients  Healthy Controls *
N   80  24 
Sex    All   Female (52)  Male (28)  F14/M11  
Age (year)  mean ± SD (range)  42.8 ± 15.1 (18–75) 39.5 ± 14.3 ^  49.1 ± 14.9  43.0 ± 12.9 
Height (m)  mean ± SD  1.73 ± 0.1  1.68 ± 0.09 ^  1.80 ± 0.08  1.76 ± 0.07 *
a 
Weight (kg)  mean ± SD  70.6 ± 15.3  66.0 ± 14.3 ^  79.1 ± 13.8  75.5 ± 11.6 
BMI (kg/m
2)  mean ± SD  23.6 ± 4.0  23.2 ± 4.2  24.3 ± 3.6  24.1 ± 2.6 
 
<18.5 
18.5–25 
>25 
6 (7.5%) 
51 (63.8%) 
23 (28.8%) 
6 (22.5%) 
31 (59.6%) 
15 (28.8%) 
0  
20 (71.4%) 
8 (28.6%) 
0 
18 (72%) 
27 (28%) 
Marsh classification  
N (%) 
I/II # 
IIIA 
IIIB 
IIIC 
9 (11.3%) 
37 (46%) 
20 (25%) 
14 (17.5%) 
6 (11.5%) 
23 (44.2%) 
10 (19.2%) 
13 (25%) 
3 (10.7%) 
14 (50.0%) 
10 (35.7%) 
1 (3.6%) 
 
Antibodies N (%)  Negative  17 (21.3%)  11 (21.1%)  6 (22.0%)   
EMA 
doubtful 
weak positive  
positive 
strong positive 
n.d. 
1 (1.3%) 
5 (6.3%) 
14 (17.5%) 
38 (47.5%) 
5 (6.3%) 
1 (1.9%) 
5 (9.6%) 
10 (19.2%) 
23 (44.2%) 
2 (3.8%) 
0 
0 
4 (14.3%) 
15 (53.6%) 
1 (3.6%) 
 
tTG 
 
Negative 
doubtful 
weak positive  
positive 
strong positive 
n.d. 
16 (20%) 
4 (5%) 
10 (12.5%) 
18 (22.5%) 
31 (38.8%) 
1 (1.3%) 
9 (17.3%) 
3 (5.8%) 
9 (17.3%) 
12 (23.1%) 
19 (36.5% 
0 
7 (25%) 
1 (3.6%) 
1 (3.6%) 
6 (21.4%) 
12 (42.9%) 
1 (3.6%) 
 
tTG (U/mL) 
mean ± SD  
(range) 
171 ± 402  
(3.2–2500) 
124 ± 378  
(4–2500) 
274 ± 445  
(3.2–1999) 
 
CD genotypes 
DQ2(hetero-/homozygote) 
DQ8(hetero-/homozygote) 
DQ2 and DQ8 
DQ2 nor DQ8 
n.d. 
62 (77.5%)(56/6) 
5 (6.3%)(3/2) 
3 (3.8%) 
3 (3.8%) 
7 (8.8%) 
42 (80.8%)(37/5) 
3 (5.8%)(2/1) 
2 (3.8%) 
1 (1.9%) 
4 (7.7%) 
20 (71.4%)(19/1) 
2 (7.1%)(1/1) 
1 (3.6%) 
2 (7.1%) 
3 (14.3%) 
 
BMI: Body Mass Index, EMA: anti-endomysial antibodies, tTG: anti-tissue transglutaminase, ^ Significantly different 
from men (p < 0.05) by Student’s t-test, n.d. (not determined), # low grade histopathological abnormalities with   
HLA-DQ2 and/or DQ8 and elevated antibodies (EMA and/or tTG), * variables NS (not statistically significant from  
CD-patients (p < 0.05) by Mann-Whitney U test), *
a statistical trend p = 0.05. 
 Nutrients 2013, 5  3982 
 
Table 3. Serum concentrations of nutritional biochemical parameters of untreated adult CD-patients (compared to healthy controls). 
Serum  
Vitamin/Mineral 
[Reference Value] 
Serum Concentration ^  Percentage deficient patients # 
All  Male  Female 
Healthy 
Controls 
All  Male  Female 
Healthy 
Controls 
Vitamin A 
[1.2–3.0 nmol/L] 
2.0 ± 0.7 
0.1–4.0 
(53) 
2.2 ± 0.9 
(17) 
1.9 ± 0.6 
(36) 
2.5 ± 0.6 
(1.4–4.0) 
%a 
(25)  
7.5% 
(4/53) 
11.8% 
(2/17) 
5.6% 
(2/36) 
0% 
(0/24) 
Vitamin B6 
[13–80 nmol/L] 
92.2 ± 142.7 
6.0–593.0 
(62) 
56.1 ± 87.1 
(20) 
109.4 ± 160.8
(42) 
70.1 ± 74.5 
(21–384) 
(25) 
14.5% 
(9/62) 
25.0% 
(5/20) 
9.5% 
(4/42) 
0% 
(0/24) 
$a 
Folic acid 
[>5.6 nmol/L] 
 
15.1 ± 15.0 
2.1–90.1 
(80) 
10.4 ± 6.6 
(28) 
17.6 ± 17.6 *
a 
(52) 
20.4 ± 18.1 
(4.4–91) 
%b  
(25) 
20.0% 
(16/80) 
28.5% 
(8/28) 
15.4% 
(8/52) 
 
4.2% 
(1/14) 
$b 
Vitamin B12 
[150–700 pmol/L) 
231.2 ± 104.3 
64.0–590.0 
(80) 
222.6 ± 75.6 
(28) 
235.7 ± 117.4
(52) 
272.6 ± 112.5 
(100–453) 
(25) 
19.0% 
(15/80) 
22.2% 
(6/27) 
17.3% 
(9/52) 
16.6% 
(4/24) 
Zinc 
[11–19 nmol/L] 
10.3 ± 2.1 
6.3–14.8 
(40) 
10.4 ± 2.2 
(16) 
10.2 ± 2.0 
(24) 
 
66.7% 
(26/40) 
62.5% 
(10/16) 
70.8% 
(17/24) 
 
Vitamin (25-hydroxy) D 
[30–150 nmol/L] 
64.8 ± 26.8 
29–120 
(21) 
64.5 ± 35.3 
(8) 
65.0 ± 21.6 
(13) 
 
4.8% 
(1/21) 
12.5% 
(1/8) 
0 
(0/13) 
 
Haemoglobin 
[M 8.5–11/F 7.5–10 mmol/L] 
8.0 ± 1.1 
5.0–10.2 
(71) 
8.9 ± 0.8 
(25) 
7.5 ± 0.9 *
b 
(46) 
 
32.4% 
(23/71) 
24.0% 
(6/25) 
37.0% 
(17/46) 
 
 
Ferritin 
[20–250 µG/L] 
48.1 ± 83.9 
3.0–451.0 
(39) 
110.9 ± 147.2
(10) 
26.4 ± 26.2 
(29) 
 
46.2% 
(18/39) 
30.0% 
(3/10) 
51.7% 
(15/29) 
 
^ Successively expressed as: mean ± SD, range, (N), * statistically significantly different from men ( Student’s t-test), *
a p = 0.04, *
b p < 0.001, # NS (not statistically significant (p < 0.05) by 
Pearson’s Chi-Square tests (χ²)), 
% statistically significantly different from CD by Mann-Whitney U test, 
%a p = 0.006, 
%b p = 0.030, 
$ statistically significant by Pearson’s Chi-Square tests (χ²),  
$a p = 0.049, 
$b p = 0.066. Nutrients 2013, 5  3983 
 
3.2. Biochemical Analyses 
Serum concentrations of vitamins and minerals of the untreated CD-patients are shown in Table 3. 
CD-patients were most frequently deficient for folic acid (20%, 16/80), followed by vitamin B12 (19%, 
15/79), vitamin B6 (14.5%, 9/62), vitamin A (7.5%, 4/53) and vitamin (25-hydroxy) D (4.5%, 1/21), 
respectively. Approximately 67% (26/39) of the patients had zinc deficiency, 32.4% (23/71) had 
anaemia, 46.2% (18/39) had insufficient iron storage evidenced by low ferritin and 25% (8/40) had 
iron-deficiency anaemia. CD-patients had lower values of vitamin A and folic acid than healthy 
controls. Overall, vitamin deficiencies were barely seen in healthy controls, with the exception of 
vitamin B12. None of the healthy controls showed deficient levels (below the reference values) for 
vitamin A and vitamin B6 and only one for folic acid. 
Ten patients (12.5%) were not deficient for any of the assessed vitamins and minerals. These patients 
had similar base-line characteristics to the rest of the CD group. The remaining 70 patients (87.5%) were 
deficient in at least one of the nutritional parameters and 43 (53.8%) for two or more parameters. 
Table 3 depicts the proportion of deficient patients, stratified by sex. As anticipated, serum 
haemoglobin concentrations were lower in women than in men (p < 0.001). While, on the other hand, 
serum folic acid concentrations were lower (p = 0.040) in men when compared to women. No 
statistically significant difference was found for any of the other nutritional parameters when 
comparing males and females. Notwithstanding, multivitamin use (including folic acid or vitamin B 
supplement) at their own volition or prescribed by the GP was more prevalent in women than men 
(30% vs. 13%). A statistical trend was seen for vitamin B6, suggesting that men might be more often 
deficient than women (p = 0.097). 
3.3. Association between Vitamin and Mineral Concentrations and Histological Damage  
(Marsh-Classification) 
Table 4 depicts the mean serum vitamin and mineral values by Marsh strata. No statistically 
significant differences were found between the serum vitamin and mineral concentrations across the 
four Marsh strata, except for ferritin. Serum ferritin values decreased when the villous atrophy score 
increased (p = 0.041). 
Table 4. Mean serum concentrations of vitamins and minerals (±SD) in untreated   
CD-patients by Marsh stratum. 
Serum  
Vitamin/Mineral 
Marsh Stratum 
I/II # 
(n = 9) 
IIIA 
(n = 37) 
IIIB 
(n = 20) 
IIIC 
(n = 14) 
Vitamin A (nmol/L) 
2.3 ± 0.4 
(4/9) 
2.0 ± 0.8 
(28/37) 
1.9 ± 0.44 
(11/20) 
1.9 ± 0.8 
(10/14) 
Vitamin B6 (nmol/L) 
129.8 ± 115.0 
(7/9) 
107.6 ± 170.7 
(29/37) 
55.7 ± 43.5 
(15/20) 
86.8 ± 163.9 
(11/14) 
Folic acid (nmol/L) 
14.1 ± 8.5 
(9/9) 
14.7 ± 12.9 
(37/37) 
13.9 ± 15.5 
(20/20) 
18.4 ± 22.4 
(14/14) 
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Table 4. Cont. 
Vitamin B12 (pmol/L) 
282.4 ± 151.7 
(9/9) 
225.2 ± 91.1 
(37/37) 
216.5 ± 80.2 
(20/20) 
234.7 ± 131.8
(14/14) 
Vitamin (25-hydroxy) D (nmol/L) 
89.3 ± 27.0 
(3/9) 
52.7 ± 16.4 
(7/37) 
63.0 ± 31.4 
(6/20) 
69.2 ± 29.2 
(5/14) 
Zinc (nmol/L) 
11.0 ± 1.7 
(5/9) 
10.8 ± 2.3  
(19/37) 
9.8 ± 1.7 
(11/20) 
8.8 ± 1.7 
(5/14) 
Haemoglobin (mmol/L) * 
8.5 ± 0.5 
(7/9) 
8.0 ± 1.2 
(33/37) 
8.0 ± 1.1 
(18/20) 
7.9 ± 1.0 
(13/14) 
Ferritin (µG/L) ^ 
123.8 ± 167.3 
(6/9) 
47.6 ± 66.3 
(18/37) 
18.8 ± 17.6 
(10/20) 
17.2 ± 22.0 
(5/14) 
# Low grade histopathological abnormalities with HLA-DQ2 and/or DQ8 and elevated antibodies (EMA and/or tTG),  
* gender specific Females I/II 8.2 ± 0.29; IIIA 7.4 ± 0.95; IIIB 7.3 ± 0.84; IIIC 7.8 ± 0.97 and Male I/II 8.9 ± 0.78;  
IIIA 8.9 ± 0.96; IIIB 9.0 ± 0.67; IIIC 8.8 ± 0.72, ^ statistically significantly different (p = 0.041) by Kruskal-Wallis test. 
3.4. Association between Vitamin and Mineral Concentrations and Nutritional Status 
Table 5 depicts the mean serum concentrations of vitamins and minerals per BMI stratum. A trend 
was observed for underweight patients having a slightly higher serum folic acid concentration than 
patients with normal weight or overweight patients (p = 0.058). Besides, patients with >10% 
unintentional weight loss in the past 6 months had higher vitamin A and (a trend for) higher vitamin B6 
(p = 0.09) levels than patients without weight loss. Otherwise, no differences were observed between 
the different classes of nutritional status. 
Table 5. Mean serum concentrations of vitamins and minerals (±SD) in untreated   
CD-patients by nutritional status (BMI stratum and unintentional weight loss). 
Serum  
Vitamin/Mineral 
BMI Stratum (kg/m
2) ^  Weight Loss (% in past 6 months) 
Under-Weight 
(<18.5) 
(n = 6) 
Normal Weight 
(18.5–25.0) 
(n = 51) 
Over-Weight
(>25) 
(n = 23) 
Well-Nourished  
(0%–10%) 
(n = 64) 
Mal-Nourished 
(>10%) 
(n = 13)  
Vitamin A (nmol/L) 
1.7 ± 0.7 
(5) 
2.0 ± 0.7 
(35) 
2.0 ± 0.6 
(13) 
1.8 ± 0.6 
(40) 
2.6 ± 0.7 # 
(11) 
Vitamin B6 (nmol/L) 
128.5 ± 207.8 
(6) 
99.3 ± 146.2 
(39) 
63.1 ± 109.0 
(17)  
68.1 ± 102.0 
(48) 
206 ± 240.8 
(11) 
Folic acid (nmol/L) 
33.0 ± 29.9 
(6) 
14.5 ± 13.4 
(51) 
11.8 ± 10.0 
(23) 
13.4 ± 11.2 
(64) 
23.5 ± 27.1 
(13) 
Vitamin B12 (pmol/L) 
216.3 ± 57.3 
(6)  
226.2 ± 114.5 
(51) 
246.0 ± 90.4 
(23) 
227.6 ± 104.0 
(64) 
250.8 ± 117.7 
(13) 
Vitamin (25-hydroxy) D 
(nmol/L) 
52.0 
(1) 
63.4 ± 28.0 
(11) 
68.0 ± 27.9 
(9) 
67.1 ± 27.1 
(17) 
55.0 ± 26.5 
(4) 
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Table 5. Cont. 
Zinc (nmol/L) 
8.8 ± 0.3 
(2) 
10.3 ± 2.1 
(26) 
10.6 ± 2.2 
(12) 
10.5 ± 2.1 
(31) 
9.8 ± 2.1 
(7) 
Haemoglobin 
(mmol/L) 
7.6 ± 0.7 
(6) 
8.0 ± 1.1 
(45) 
8.2 ± 1.2 
(20) 
8.1 ± 1.1 
(56) 
7.8 ± 1.4 
(12) 
Ferritin (µG/L) 
25.0 ± 2.1 
(3) 
34.9 ± 38.4 
(26) 
89.0 ± 151.9 
(10) 
48.5 ± 90.4 
(33) 
46.2 ± 38.3 
(5) 
^ NS (not statistically significant (p < 0.05) by Kruskal-Wallis test, #  statistically significantly different from  
well-nourished patients (Student t-test), p = 0.001. 
4. Discussion 
The present study showed that the majority of an “early diagnosis” adult untreated CD patient group 
(with so-called non-classical presentation) in the Netherlands, had at least one, and often several, 
serum vitamin or mineral deficiencies at diagnosis. Almost 90% of CD-patients were found to be 
deficient in at least one or more of the assessed nutritional parameters, and half of patients were 
deficient for two or more nutritional serum variables. This was observed to be unrelated to severity of 
clinical presentation, nutritional status or (semi-quantified) histopathological damage (score). 
In this study, no statistically significant difference in serum vitamin and mineral concentration was 
found between men and women, although (multi)vitamin use prior to diagnosis was more prevalent in 
women than men (30% vs. 13%). Information is lacking whether they took the vitamins at their own 
volition, or if they were prescribed by the general practitioner. In addition, the assessed serum 
deficiencies were independent of Marsh stratum (Table 4), nutritional status (Table 5) and age (data 
not shown). Folic acid deficiency was observed in 20% of the untreated CD-patients in this study. The 
prevalence of folate deficiency varies from 18% to 90% in varying older and newer reports of   
CD-patients [17,18,24,26]. In studies from Scotland and Finland, folate deficiency was reported in 
42% [18] and 37% [27] of the untreated CD-patients, respectively. The difference in prevalence might 
at least partially be explained by technical aspects of measurement of “folate” (which is the natural 
form of folic acid) and “folic acid” since bioavailability of folic acid is twice that of folate [40]. 
Macrocytic anaemia in untreated CD-patients is usually caused by folate deficiency. In two large 
European studies, anaemia, mostly attributed to malabsorption, was reported to be present in 20%–34% 
of untreated CD-patients [20,30]. This corresponds with our results in which 25% of the CD-patients 
suffered from iron-deficiency anaemia. 
The presence of vitamin B6 deficiency has been reported in two studies, albeit in children with 
“acute celiac disease”. A decreased pyridoxal phosphate was reported in serum samples and in 
duodenal mucosa, suggestive of vitamin B6 deficiency [41,42] and indicative for decreased levels of 
vitamin B6 in untreated CD children. We found water-soluble vitamin deficiencies (B6, folic acid and 
B12) in approximately one in seven (B6) to one in five (folic acid and B12) untreated CD-patients. This 
was despite the fact that more than 20% of the patients were using a prescribed or over-the-counter 
multivitamin/vitamin B-complex or a folic acid supplement before diagnosis. 
Vitamin B12 deficiency was frequently observed in our CD-patient group (19%), in accordance with 
earlier studies, notably also in those without atrophic gastritis [17,18,26–28]. Intriguingly, this vitamin 
is typically absorbed in the terminal ileum. Apparently, the distal small bowel is functionally more Nutrients 2013, 5  3986 
 
affected than previously believed, based on patho-histological analysis of distal small bowel biopsy 
samples [43]. Vitamin B12 deficiency in untreated CD-patients has been confirmed in several 
previously conducted European studies [18,25–28], ranging from 12% up to 41%. It may be 
hypothesized that vitamin B12 deficiency is a result of a dysfunctional intrinsic factor [44]. Dickey 
reported that low vitamin B12 concentrations in CD were not due to auto-immune gastritis [28]. In this 
study, none of the patients had histologically or serologically demonstrated atrophic gastritis and, 
therefore, this was unlikely to be responsible for vitamin B12 deficiencies in CD. 
In various small studies in Europeans, deficiencies of the fat soluble vitamins A [23,27], E [19,29] 
and D [45] in untreated CD-patients have been previously reported. The latter has been associated with 
osteomalacia. In clinical practice, many believe that the clinically relevant lower limit for vitamin D 
deficiency should be increased. As a consequence, the displayed (relatively low) deficiency 
percentages can therefore be an underestimation. The observed 7.5% of vitamin A deficient patients is 
less than the percentage reported in Finland (14%) for this vitamin [27]. From healthy subject studies, 
it is known that the vitamin A body storage is usually stable and sufficient for approximately one to two 
years [46]. This is confirmed by our healthy sample, in which none of the subjects showed a deficiency. 
A majority of our untreated CD-patients had a zinc deficiency, which can probably be explained by 
increased endogenous losses of zinc, rather than abnormal zinc absorption [20]. Clinical relevance of 
zinc deficiency remains inconclusive and additional research is warranted. However, it is known that 
CD is associated with a wide array of skin lesions and manifestations, which may be partly ascribed to 
zinc deficiency [47–50], and cell mediated immunity and antioxidant buffer capacity may be 
compromised due to it as well [51]. 
Possible explanations for the high prevalence of nutritional deficiencies in untreated CD-patients 
might be an insufficient nutritional intake. This is supported by the presence of malnutrition in this 
cohort: 17% was malnourished based on the usual definition of >10% involuntary body weight loss 
prior to diagnosis and 7.5% had a BMI <18.5 kg/m
2. However, this seemed unlikely since patients did 
not report any changes (intentional or involuntary) in their habitual diet before diagnosis. Moreover, 
the observed presence of high serum folate levels, particularly in those classified as underweight, were 
contradictory as well. On the other hand, increased faecal losses of nutrients as a result of 
malabsorption might (partially) explain the high prevalence of deficiencies. However, since most 
patients did not report any clinical sign of malabsorptive diarrhoea, losses via the stools were thought 
to be of limited importance as well. Nevertheless, the observed findings in this study, sharing 
deficiencies in water and fat soluble vitamins, zinc and iron, indicate that maldigestion, malabsorption 
or a structurally moderately inadequate intake might have been present long before the clinical 
diagnosis of CD was established. It is known that the delay in diagnosing CD can be more than a 
decade [52]. One may hypothesize that this might be due to functional changes of the intestinal tract or 
due to changes in the intestinal microbiome [53]. In this study, even patients with mild CD (low grade 
pathohistological abnormalities) showed nutritional deficiencies and weight loss. A finding that was 
recently corroborated in a large Italian cohort showed that mild (histopathological) enteropathy did not 
necessarily mean mild intestinal dysfunction since, also in this group, alterations in bone marrow 
density and laboratory parameters were reported [54]. Remarkably, only female patients presented as 
underweight (approximately one in four females), while the female-male ratio was similar in the 
overweight and obese patients. A statistical trend for higher serum vitamin A and B concentrations was Nutrients 2013, 5  3987 
 
observed in patients classified as malnourished (low BMI or >10% unintentional weight loss prior to 
diagnosis). This may be explained by their more so-called classical CD presentation, which may 
trigger use of supplements due to a greater physicians’ or patients’ awareness when observing clinical 
signs of malnutrition. 
Some considerations arise when interpreting the presented results: not all data were available in all 
subjects and some subgroups were relatively small, precluding detection of small effects or the 
drawing of firm conclusions in subgroups. Vitamin or mineral supplement use, whether at the patient’s 
own initiative or prescribed by the GP, was based on self-reported information and can therefore be 
underestimated if patients forget to mention these “medicinal supplements”. However, real numbers 
and frequencies of deficiencies or anaemia might be underestimated, since some patients were already 
taking these supplements before the initial diagnosis of CD, potentially leading to misclassification as 
“non-deficient” in this study. Besides, serum values of almost all vitamins or minerals do not fully 
represent total body stock or physiological function. 
Based on our experience and supported by a recently published guideline on CD [3], we suggest 
monitoring body weight at diagnosis and nutritional serum parameters; at least vitamin B6, folic acid, 
B12 and zinc and in any case (25-hydroxy) D of the fat soluble vitamins (due to its connection with 
presence of osteomalacia). Moreover, we suggest follow-up until serum values are at satisfying levels 
or upon indication (for instance, if bone density deviations, chronic diarrhoea, or skin lesions are 
present). Practically, a standard complete multivitamin supplement (100%–300% of RDA) should be 
considered for every newly diagnosed CD-patient. Continuation time has yet to be determined, since 
patients are at risk for vitamin deficiencies even after 10 years of a GFD [55]. Evidently, 
hypervitaminosis should be avoided, in particular regarding pyridoxine and iron [56,57]. It is 
demonstrated that bone-mineral density and nutritional status can improve after a GFD treatment [58] 
as well as that of general well-being, which can improve after vitamin B supplementation in   
CD-patients on a GFD [59]. 
5. Conclusions 
In conclusion, deficiencies of vitamins or minerals are frequently observed in untreated adult Dutch 
CD-patients using a Western diet, although they are currently diagnosed earlier than in the previous 
century. This was observed even in obese patients. Almost 90% of the newly diagnosed CD-patients 
had one or more nutritional deficiencies. Malnutrition, expressed as an involuntary weight loss or 
being underweight, was found in 16% and 7.5% of patients, respectively, while overweight status 
(BMI > 25 kg/m
2) was present in almost 30% of the patients. Therefore, these results indicate that 
extensive nutritional assessment of body weight and serum nutritional parameters should be an integral 
part of celiac disease treatment to guide nutritional advices and follow-up in CD-treatment by means 
of an adequately composed individual-based, gluten free diet. 
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